Max S. Topp

Oberduerrbacher Str. 6
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 129 publications

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: May 22, 2026

BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma.

BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma.

Journal: JAMA oncology

Published: February 05, 2026

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Journal: Leukemia

Published: January 31, 2026

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal: Journal of hematology & oncology

Published: December 30, 2025

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Leukemia

Published: November 19, 2025

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal

Published: November 01, 2025

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Journal: British journal of haematology

Published: October 17, 2025

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.

Journal: Blood advances

Published: August 11, 2025

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.

Journal: Blood advances

Published: August 11, 2025

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Journal: HemaSphere

Published: August 06, 2025

Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.

Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.

Journal: Blood cancer discovery

Published: July 31, 2025

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

Journal: Blood

Published: May 09, 2025

Showing 1-12 of 129

Last Updated: 09/26/2026